Aberrant chromatin remodeling in gynecological cancer (Review)

Ryuichiro Okawa, Kouji Banno, Miho Iida, Megumi Yanokura, Takashi Takeda, Moito Iijima, Haruko Kunitomi Irie, Kanako Nakamura, Masataka Adachi, Kiyoko Umene, Yuya Nogami, Kenta Masuda, Yusuke Kobayashi, Eiichirou Tominaga, Daisuke Aoki

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Epigenetic regulatory mechanisms are a current focus in studies investigating cancer. Chromatin remodeling alters chromatin structure and regulates gene expression, and aberrant chromatin remodeling is involved in carcinogenesis. AT-rich interactive domain-containing protein 1A (ARID1A) and SWItch/sucrose non-fermentable-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 are remodeling factors that are mutated in numerous types of cancer. In gynecological cancer, ARID1A mutations have been identified in 46-57% of clear cell carcinoma and 30% of endometrioid carcinoma. Mutations of chromodomain helicase, DNA-binding protein 4 have been detected in 17-21% of endometrial serous cancer, and mutations of ARID1A and mixed-lineage leukemia 3 occur in 36 and 27% of uterine carcinosarcoma, respectively. These data suggest that aberrant chromatin remodeling is a potential cause of cancer, and have led to the development of novel proteins targeting these processes. Additional accumulation of information on the mechanisms of chromatin remodeling and markers for these events may promote personalized anticancer therapies.

Original languageEnglish
Pages (from-to)5107-5113
Number of pages7
JournalOncology Letters
Volume14
Issue number5
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Chromatin Assembly and Disassembly
Mutation
Chromatin
Myeloid-Lymphoid Leukemia Protein
Neoplasms
Endometrioid Carcinoma
Carcinosarcoma
DNA-Binding Proteins
Protein Transport
Endometrial Neoplasms
Epigenomics
Sucrose
Actins
Carcinogenesis
Carcinoma
Gene Expression
Protein Domains
Therapeutics

Keywords

  • AT-rich interaction domain 1A
  • Carcinogenesis
  • Chromatin remodeling
  • Gynecological cancer
  • Mutation
  • Switch/sucrose non-fermentable complex

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aberrant chromatin remodeling in gynecological cancer (Review). / Okawa, Ryuichiro; Banno, Kouji; Iida, Miho; Yanokura, Megumi; Takeda, Takashi; Iijima, Moito; Irie, Haruko Kunitomi; Nakamura, Kanako; Adachi, Masataka; Umene, Kiyoko; Nogami, Yuya; Masuda, Kenta; Kobayashi, Yusuke; Tominaga, Eiichirou; Aoki, Daisuke.

In: Oncology Letters, Vol. 14, No. 5, 01.11.2017, p. 5107-5113.

Research output: Contribution to journalReview article

Okawa, R, Banno, K, Iida, M, Yanokura, M, Takeda, T, Iijima, M, Irie, HK, Nakamura, K, Adachi, M, Umene, K, Nogami, Y, Masuda, K, Kobayashi, Y, Tominaga, E & Aoki, D 2017, 'Aberrant chromatin remodeling in gynecological cancer (Review)', Oncology Letters, vol. 14, no. 5, pp. 5107-5113. https://doi.org/10.3892/ol.2017.6891
Okawa, Ryuichiro ; Banno, Kouji ; Iida, Miho ; Yanokura, Megumi ; Takeda, Takashi ; Iijima, Moito ; Irie, Haruko Kunitomi ; Nakamura, Kanako ; Adachi, Masataka ; Umene, Kiyoko ; Nogami, Yuya ; Masuda, Kenta ; Kobayashi, Yusuke ; Tominaga, Eiichirou ; Aoki, Daisuke. / Aberrant chromatin remodeling in gynecological cancer (Review). In: Oncology Letters. 2017 ; Vol. 14, No. 5. pp. 5107-5113.
@article{6a6191371a0940e3b6e51abae6ae6a90,
title = "Aberrant chromatin remodeling in gynecological cancer (Review)",
abstract = "Epigenetic regulatory mechanisms are a current focus in studies investigating cancer. Chromatin remodeling alters chromatin structure and regulates gene expression, and aberrant chromatin remodeling is involved in carcinogenesis. AT-rich interactive domain-containing protein 1A (ARID1A) and SWItch/sucrose non-fermentable-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 are remodeling factors that are mutated in numerous types of cancer. In gynecological cancer, ARID1A mutations have been identified in 46-57{\%} of clear cell carcinoma and 30{\%} of endometrioid carcinoma. Mutations of chromodomain helicase, DNA-binding protein 4 have been detected in 17-21{\%} of endometrial serous cancer, and mutations of ARID1A and mixed-lineage leukemia 3 occur in 36 and 27{\%} of uterine carcinosarcoma, respectively. These data suggest that aberrant chromatin remodeling is a potential cause of cancer, and have led to the development of novel proteins targeting these processes. Additional accumulation of information on the mechanisms of chromatin remodeling and markers for these events may promote personalized anticancer therapies.",
keywords = "AT-rich interaction domain 1A, Carcinogenesis, Chromatin remodeling, Gynecological cancer, Mutation, Switch/sucrose non-fermentable complex",
author = "Ryuichiro Okawa and Kouji Banno and Miho Iida and Megumi Yanokura and Takashi Takeda and Moito Iijima and Irie, {Haruko Kunitomi} and Kanako Nakamura and Masataka Adachi and Kiyoko Umene and Yuya Nogami and Kenta Masuda and Yusuke Kobayashi and Eiichirou Tominaga and Daisuke Aoki",
year = "2017",
month = "11",
day = "1",
doi = "10.3892/ol.2017.6891",
language = "English",
volume = "14",
pages = "5107--5113",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Aberrant chromatin remodeling in gynecological cancer (Review)

AU - Okawa, Ryuichiro

AU - Banno, Kouji

AU - Iida, Miho

AU - Yanokura, Megumi

AU - Takeda, Takashi

AU - Iijima, Moito

AU - Irie, Haruko Kunitomi

AU - Nakamura, Kanako

AU - Adachi, Masataka

AU - Umene, Kiyoko

AU - Nogami, Yuya

AU - Masuda, Kenta

AU - Kobayashi, Yusuke

AU - Tominaga, Eiichirou

AU - Aoki, Daisuke

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Epigenetic regulatory mechanisms are a current focus in studies investigating cancer. Chromatin remodeling alters chromatin structure and regulates gene expression, and aberrant chromatin remodeling is involved in carcinogenesis. AT-rich interactive domain-containing protein 1A (ARID1A) and SWItch/sucrose non-fermentable-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 are remodeling factors that are mutated in numerous types of cancer. In gynecological cancer, ARID1A mutations have been identified in 46-57% of clear cell carcinoma and 30% of endometrioid carcinoma. Mutations of chromodomain helicase, DNA-binding protein 4 have been detected in 17-21% of endometrial serous cancer, and mutations of ARID1A and mixed-lineage leukemia 3 occur in 36 and 27% of uterine carcinosarcoma, respectively. These data suggest that aberrant chromatin remodeling is a potential cause of cancer, and have led to the development of novel proteins targeting these processes. Additional accumulation of information on the mechanisms of chromatin remodeling and markers for these events may promote personalized anticancer therapies.

AB - Epigenetic regulatory mechanisms are a current focus in studies investigating cancer. Chromatin remodeling alters chromatin structure and regulates gene expression, and aberrant chromatin remodeling is involved in carcinogenesis. AT-rich interactive domain-containing protein 1A (ARID1A) and SWItch/sucrose non-fermentable-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 are remodeling factors that are mutated in numerous types of cancer. In gynecological cancer, ARID1A mutations have been identified in 46-57% of clear cell carcinoma and 30% of endometrioid carcinoma. Mutations of chromodomain helicase, DNA-binding protein 4 have been detected in 17-21% of endometrial serous cancer, and mutations of ARID1A and mixed-lineage leukemia 3 occur in 36 and 27% of uterine carcinosarcoma, respectively. These data suggest that aberrant chromatin remodeling is a potential cause of cancer, and have led to the development of novel proteins targeting these processes. Additional accumulation of information on the mechanisms of chromatin remodeling and markers for these events may promote personalized anticancer therapies.

KW - AT-rich interaction domain 1A

KW - Carcinogenesis

KW - Chromatin remodeling

KW - Gynecological cancer

KW - Mutation

KW - Switch/sucrose non-fermentable complex

UR - http://www.scopus.com/inward/record.url?scp=85030175423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030175423&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.6891

DO - 10.3892/ol.2017.6891

M3 - Review article

VL - 14

SP - 5107

EP - 5113

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 5

ER -